Learn more about Rena Conti

Rena M. Conti is an Assistant Professor of Health Policy at The University of Chicago, Department of Pediatrics, Section of Hematology/Oncology, and Department of Public Health Sciences.

Recent Posts by Rena Conti

New Cures Require New Pricing Policies

One critical incentive for ongoing drug discovery and development is the temporary monopoly pricing that manufacturers can command for novel drugs. Yet this incentive, embedded in current patent and regulatory policy, does not guarantee that manufacturers will deliver novel products with...

April 16, 2015Health Policy Lab

Why Are Cancer Drugs Commonly The Target Of Schemes To Extend Patent Exclusivity?

The makers of branded pharmaceuticals have devised numerous ways to extend patent exclusivity for lucrative products in the United States. In June, the Supreme Court gave the Federal Trade Commission (FTC) clear authority to investigate and prosecute one of them, “pay-for-delay” agreements, but...

Winners And Losers From The Zaltrap Price Discount: Unintended Consequences?

Soon after Sanofi Pharmaceuticals’ Inc. August 2012 launch of the biologic drug ziv-aflibercept (brand name Zaltrap) into the U.S. market, its price triggered an unusual act of defiance on the part of oncolAogists. Physicians from Memorial Sloan-Kettering Cancer Center stated in a New York...